• Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Unspecified (DepMap).
  

PubMed=1979248
Kubonishi I., Sonobe H., Miyagi T., Iwahara Y., Ohyashiki J.H., Ohyashiki K., Toyama K., Ohtsuki Y., Miyoshi I.
A Ki-1 (CD30)-positive T (E+, CD4+, Ia+)-cell line, DL-40, established from aggressive large cell lymphoma.
Cancer Res. 50:7682-7685(1990)

PubMed=8957066; DOI=10.1111/j.1349-7006.1996.tb03112.x
Kawasaki N., Matsuo Y., Yoshino T., Yanai H., Oka T., Teramoto N., Liu C., Kondo E., Minowada J., Akagi T.
Metastatic potential of lymphoma/leukemia cell lines in SCID mice is closely related to expression of CD44.
Jpn. J. Cancer Res. 87:1070-1077(1996)

PubMed=10639591; DOI=10.3892/ijmm.5.2.139
Ogawa Y., Nishioka A., Inomata T., Kataoka S., Nakayama K.-I., Kariya S., Terashima M., Kubonishi I., Yoshida S.
Ionizing radiation-induced apoptosis in human lymphoma cell lines differing in p53 status.
Int. J. Mol. Med. 5:139-143(2000)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=15356658; DOI=10.1038/sj.leu.2403465
Drexler H.G., MacLeod R.A.F.
Malignant hematopoietic cell lines: in vitro models for the study of anaplastic large-cell lymphoma.
Leukemia 18:1569-1571(2004)

PubMed=28356514; DOI=10.1073/pnas.1700682114
Chen J., Zhang Y., Petrus M.N., Xiao W.-M., Nicolae A., Raffeld M., Pittaluga S., Bamford R.N., Nakagawa M., Ouyang S.T.-Y., Epstein A.L., Kadin M.E., Del Mistro A., Woessner R.D., Jaffe E.S., Waldmann T.A.
Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Proc. Natl. Acad. Sci. U.S.A. 114:3975-3980(2017)